The most common side effects of ENTYVIO include: common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, and pain in extremities. These are not all the possible side effects of ENTYVIO.

by Drugs.com The list price for a 30-day supply of intravenous (IV) or subcutaneous (SC) Entyvio is $4,380.01 or $52,560.12 per year. Your final cost will depend upon your insurance coverage or copays.

This medication is used to treat certain bowel disorders (ulcerative colitis, Crohn's disease). In these conditions, the body's defense system (immune system) attacks healthy tissues in the gut, causing symptoms such as abdominal pain, blood in the stool, and diarrhea.

Vedolizumab (Entyvio, Takeda Pharmaceuticals), a monoclonal antibody to the α4β7 integrin, inhibits gut lymphocyte trafficking and has been demonstrated to be an effective and safe agent for the treatment of both Crohn's disease and ulcerative colitis.

Serious infection In very rare cases, Entyvio can lead to a viral infection in the brain. This is called progressive multifocal leukoencephalopathy (PML). People who already have a weak immune system are at higher risk of PML. For most people, the virus that causes this condition is nothing to worry about.

You may receive "killed-virus" vaccines such as a flu shot, polio vaccine, rabies vaccine, or hepatitis A vaccine. Ask your doctor before receiving any vaccine while you are being treated with Entyvio. Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

VEDOLIZUMAB

Different parts of Medicare may cover portions of the cost of Entyvio. For example, if you have a Part D plan, it may cover the Entyvio injection price. If you have Medicare Part B, it may cover your visit to your doctor's office or clinic where you receive your infusion.

Yes, Entyvio is meant to be used as a long-term treatment. How long you'll receive Entyvio depends depends on whether the drug is working to manage the symptoms of your condition. If you and your doctor determine that Entyvio is safe and effective for you, it's likely that you'll be given it long term.

In two intravenous (IV) Entyvio studies of 307 patients going out to one year, 39% of patients receiving Entyvio were in remission and 44% of patients had a clinical response, at the end of the trial, compared to 22% and 30% of patients who received a placebo, respectively.

Every patient reacts differently to medication treatment and has a different level of disease severity. Not every patient will respond to Entyvio. If after 14 weeks you have not experienced a therapeutic benefit with Entyvio your doctor may consider discontinuing Entyvio treatment.

For people with infections: Entyvio can worsen infections. If you have symptoms of an infection, such as a fever or cough, you may not be able to use Entyvio until the infection has cleared. For people with liver disease: Entyvio may worsen liver problems in those who already have liver disease.